| Project Id
|
BITSRMIT024B001303
|
| Project Detail
|
| Project Title
|
Design and evaluation of nanocarriers-mediated topical delivery of combined chemo-photodynamic agents in psoriasis treatment
|
| Senior Supervision Team (BITS)
|
| Supervisor name and Title
|
Gautam Singhvi
|
School or Department (or company, if applicable)
|
BITS PILANI, PILANI CAMPUS
|
|
|
|
Email ID
|
gautam.singhvi@pilani.bits-pilani.ac.in
|
| URL for more info
|
https://www.bits-pilani.ac.in/pilani/gautam-singhvi
|
| a) Are you currently supervising a BITS or RMIT HDR student?
|
YES
|
| Please comment how many you are supervising
|
4
|
| b) Have you supervised an offshore candidate before?
|
NO
|
| If no, what support structures do you have in place?
|
|
| If yes, please elaborate
|
N
|
| Senior Supervision Team (RMIT)
|
| Supervisor name and Title
|
Rajesh Ramanathan, Professor
|
School or Department (or company, if applicable)
|
STEM
|
|
|
|
Email ID
|
rajesh.ramanathan@rmit.edu.au
|
| URL for more info
|
https://www.rmit.edu.au/contact/staff-contacts/academic-staff/r/ramanathan-professor-rajesh
|
| a) Are you currently supervising a BITS or RMIT HDR student?
|
YES
|
| Please comment how many you are supervising
|
10
|
| b) Have you supervised an offshore candidate before?
|
YES
|
| If no, what support structures do you have in place?
|
|
| If yes, please elaborate
|
Fortnightly meeting with students and supervisors to ensure progress. In the case of a joint PhD program, the supervisors from the other institution are also involved so that the student gets maximum benefit working in a collaborative environment.
|
| Other Supervisors (BITS)
|
| Supervisor name and Title
|
|
School or Department (or company, if applicable)
|
|
| Phone Number (Optional)
|
|
Email ID
|
|
| URL for more info
|
|
| Other Supervisors (BITS)
|
| Supervisor name and Title
|
Vipul Bansal
|
School or Department (or company, if applicable)
|
STEM
|
| Phone Number (Optional)
|
61430351326
|
Email ID
|
vipul.bansal@rmit.edu.au
|
| URL for more info
|
https://www.rmit.edu.au/contact/staff-contacts/academic-staff/b/bansal-professor-vipul
|
| Field of Research (For Codes)
|
| 310607 | Nanobiotechnology | 40.00 |
| 320403 | Autoimmunity | 20.00 |
| 320604 | Nanomedicine | 40.00 |
|
| Project Description
|
|
Psoriasis, a chronic autoimmune condition, affects 2-3% of the global population. In India, prevalence ranged from 0.4% to 0.54% between 2010 and 2020, according to the Global Psoriasis Atlas. Developing targeted medications with the advancements in drug delivery technologies, for localized administration of anti-psoriatic medications, has the potential to enhance treatment outcomes. Incorporating photodynamic therapy as an additional approach in psoriasis treatment can offer promising results by synergistically targeting both the immune response and the proliferation of skin cells. A comprehensive approach with advanced technology using integrated photodynamic therapy and anti-psoriatic agent is essential for improving treatment outcomes. Advanced technologies such as nanocarriers-based drug delivery show promise in improving the efficacy and safety of topical psoriasis treatments by enabling enhanced drug penetration, prolong drug retention at the site of action, and reduce systemic exposure.
Therefore the objective of the proposed research work is to explore the combined chemo-photodynamic therapy for psoriasis treatment with nanocarriers for site specific topical delivery. To achieve this, in-vitro investigation of combination index for chemo and photodynamic agent will be performed. The selected combination will be loaded to in-house design nanocarriers system. Further, therapeutic agents loaded nanocarriers will be evaluated for physicochemical characterization, in-vitro cell line study, ex-vivo permeation and in-vivo efficacy in the disease-induced animal model. It is expected that the proposed strategy will provide industrial feasible nanoformulation with improved therapeutic efficacy in the treatment of psoriasis.
|
| Project Deliverable/Outcomes
|
|
•Innovative technology enhancing psoriasis treatment efficacy through synergistic approaches. Integration of combination therapy to optimize treatment efficiency and synergistic effects.
•The project will develop efficient nanocarriers based drug delivery system for co-delivery of anti-psoriatic and photodynamic agents.
•Streamlined, cost-effective manufacturing process for scalable product delivery.
•Nanocarrier design prioritizing therapy improvement, patient acceptance, and long-term adherence.
•Emphasis on nanocarrier design simplicity, translational potential, and stability.
•Expected creation of Intellectual Property via patents and publications.
•Opportunity for a research scholar to participate in the project, with the assurance of pursuing a PhD program.
|
| Research Impact Themes
|
| BETTER HEALTH OUTCOMES | AFFORDABLE HEALTH AND PREVENTABLE DISEASES |
| BETTER HEALTH OUTCOMES | HEALTH INNOVATION AND BIOMEDICAL AND WEARABLE DEVICES |
|
| Which RMIT Sustainable Development Goal (SDG) does your project align to
|
|
GOOD HEALTH AND WELLBEING
|
| Which RMIT Enabling Impact Platform (EIP) does your project align to
|
|
BIOMEDICAL AND HEALTH INNOVATION
|
| Which RMIT Program code will this project sit under?
|
|
DR229 (CHEM AND ENVIRO)
|
| Student Capabilities and Qualifications
|
|
First class in M.PHARM / M.S in Pharmaceutics, Pharmacology, Pharm-Biotechnology, nanomedicines, or equivalent from a recognized University
|
|
Experience in nanocarriers design, cell line study, and animal study will be preferred.
|
|
M.PHARM/M.S/M.Tech
|
| Preferred discipline of Student
|
| Nanotechnology, Nanomaterials, Nanomedicine, Nanoscience |
| Pharmaceautical Sciences, Pharmacology |
| Pharmaceutical Sciences |
|